Clinical Trial Update: The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study evaluating how ANS-6637 affects midazolam pharmacokinetics in healthy volunteers; results completed and posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• ANS-6637
• Midazolam (Midazolam)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Opiod Use Disorder | Phase 1 | Status: COMPLETED | Results posted: 2020-08-03